ARQT Arcutis Biotherapeutics Inc

Price (delayed)

$25.83

Market cap

$3.25B

P/E Ratio

123

Dividend/share

N/A

EPS

$0.21

Enterprise value

$3.33B

?
Relative Growth: Rel. Growth: 93
Relative Strength: Rel. Strength: 70
Relative Valuation: Rel. Valuation: 21
Relative Profitability: Rel. Profitability: 88

Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment ...

Highlights
Arcutis Biotherapeutics's net income has surged by 131% YoY
ARQT's EPS has soared by 128% YoY
Arcutis Biotherapeutics's quick ratio has decreased by 14% YoY but it has increased by 9% QoQ
Arcutis Biotherapeutics's debt has increased by 3.6% YoY

Key stats

What are the main financial stats of ARQT

ARQT stock price

How has the Arcutis Biotherapeutics stock price performed over time
Intraday
-1.71%
1 week
-2.27%
1 month
-4.76%
1 year
65.26%
YTD
-11.05%
QTD
-1.49%

Financial performance

How have Arcutis Biotherapeutics's revenue and profit performed over time
Revenue
$463.98M
Gross profit
$422.89M
Operating income
$34.25M
Net income
$28.52M
Gross margin
91.1%
Net margin
6.1%
The company's operating income has surged by 140% YoY
Arcutis Biotherapeutics's net income has surged by 131% YoY
The operating margin has soared by 123% YoY
Arcutis Biotherapeutics's net margin has surged by 117% YoY

Price vs fundamentals

How does ARQT's price correlate with its fundamentals

Growth

What is Arcutis Biotherapeutics's growth rate over time

Valuation

What is Arcutis Biotherapeutics stock price valuation
P/E
123
P/B
14.65
P/S
7.27
EV/EBIT
77.1
EV/EBITDA
73.28
EV/Sales
7.17
ARQT's EPS has soared by 128% YoY
The stock's price to book (P/B) is 81% more than its 5-year quarterly average of 8.1 but 7% less than its last 4 quarters average of 15.8
Arcutis Biotherapeutics's equity has surged by 59% YoY and by 16% QoQ
The price to sales (P/S) is 94% lower than the 5-year quarterly average of 123.4 and 9% lower than the last 4 quarters average of 8.0
The company's revenue has surged by 76% YoY and by 12% QoQ

Efficiency

How efficient is Arcutis Biotherapeutics business performance
The company's return on invested capital has surged by 148% YoY
ARQT's ROS has soared by 133% YoY
ARQT's return on assets has surged by 126% year-on-year
The ROE has soared by 124% YoY

Dividends

What is ARQT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ARQT.

Financial health

How did Arcutis Biotherapeutics financials performed over time
ARQT's total assets is 82% greater than its total liabilities
ARQT's total assets is up by 39% year-on-year and by 6% since the previous quarter
The total liabilities has increased by 26% YoY
Arcutis Biotherapeutics's debt is 48% lower than its equity
Arcutis Biotherapeutics's equity has surged by 59% YoY and by 16% QoQ
ARQT's debt to equity is down by 34% year-on-year and by 13% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.